Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Nattakorn Dhiantravan, John Violet, Renu Eapen, Omar Alghazo, Mark Scalzo, Price Jackson, Simon P. Keam, Catherine Mitchell, Paul J. Neeson, Shahneen Sandhu, Scott G. Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S. Hofman, Declan G. Murphy

Research output: Contribution to journalArticleOtherpeer-review

13 Citations (Scopus)


LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium-177–radiolabelled small molecule PSMA-617 in men with high-risk localised/locoregional advanced prostate cancer with high prostate-specific membrane antigen expression who are undergoing radical prostatectomy and pelvic lymph node dissection.

Original languageEnglish
Pages (from-to)234-237
Number of pages4
JournalEuropean Urology Focus
Issue number2
Publication statusPublished - Mar 2021
Externally publishedYes

Cite this